Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
about
Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status.Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.Epidermal growth factor receptor inhibitors in cancer treatment.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyLessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.Gefitinib in the treatment of advanced non-small-cell lung cancer.Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Safety of gefitinib in non-small cell lung cancer treatment.Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
P2860
Q34001991-589E84B2-E8D8-4BCC-B9FE-2ADB85EF255EQ34575903-6B84DE27-5D9E-46EE-BBEF-0F10E643B46BQ35980560-2592EA36-98F7-4AE1-8A01-F135A6048A73Q36135604-0C4933C8-7A5B-42EA-9869-172BCBF59A2EQ36429442-E11F4106-C168-4B41-BE4A-96B1E22B89F8Q37347532-B4A54E6E-8CD8-4AE7-AEA0-3C4FE3A0E591Q37360492-0B6884AF-D780-4D07-BB61-CD1848D31EDCQ37449013-94F6B463-9119-43E5-A39B-5DA65A579C85Q37509502-805140D7-8CA5-444D-A74E-0D0731038FADQ37873453-A9EEAE44-5BD5-4BAD-B404-7304D879BBA0Q38594474-BBB670BF-BFCC-40D3-AB44-A1F8FBE90D90Q38601725-2F18E90E-1DCF-4452-AC6A-E5A48D387210Q38841473-CB79BB82-FA1E-4AA1-BBB6-BA08843D6E2FQ46731927-9DE24C22-5B58-444F-B51D-CB5FCE09B20EQ46755113-CADA0BDE-D394-4023-8DA5-617746EB982CQ54582444-FECFF698-D55D-477A-BD30-A95A936B305E
P2860
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@ast
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@en
type
label
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@ast
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@en
prefLabel
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@ast
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@en
P2093
P2860
P356
P1476
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601387
P407
P577
2003-11-01T00:00:00Z
P5875
P6179
1050046529